Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis
Author(s) -
Sudhir Venkatesan,
Puja Myles,
Jo LeonardiBee,
Stella G. Muthuri,
Malak Al Masri,
Nick Andrews,
Carlos Bantar,
Gal DubnovRaz,
Patrick Gérardin,
Evelyn Siew-Chuan Koay,
Tze Ping Loh,
Ziad A. Memish,
Elizabeth Miller,
Maria E. Oliva,
Barbara A. Rath,
Brunhilde Schweiger,
Julian W. Tang,
Dat Tran,
Tjasa Vidmar,
Pauline A. Waight,
Jonathan S. NguyenVanTam
Publication year - 2017
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cix127
Subject(s) - medicine , odds ratio , confidence interval , logistic regression , neuraminidase inhibitor , propensity score matching , population , emergency medicine , pediatrics , covid-19 , disease , environmental health , infectious disease (medical specialty)
While evidence exists to support the effectiveness of neuraminidase inhibitors (NAIs) in reducing mortality when given to hospitalized patients with A(H1N1)pdm09 virus infection, the impact of outpatient treatment on hospitalization has not been clearly established. We investigated the impact of outpatient NAI treatment on subsequent hospitalization in patients with A(H1N1)pdm09 virus infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom